Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
cePolyTregs for ARDS Associated with COVID-19
NCT05027815Phase 1Terminated
- Start
- Sep 2021
- Primary completion
- Mar 2022
- Modality
- Regulatory T Cells (Tregs)
- Countries
- 1
01
Overview
Phase 1, open-label trial of cePolyTregs in acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) (3 arms). Primary endpoint: Dose-Limiting Toxicities at 28 days. Started Sep 2021; status: terminated.
02
Drugs
cePolyTregs
03
Conditions
acute respiratory distress syndrome (ARDS)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05027815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05027815.